Eli Lilly adds virtual primary care option for Alzheimer's evaluations

The news: Eli Lilly added a virtual primary care option for people with memory concerns through a partnership with General Medicine, per Endpoints News. Clinicians can conduct initial memory assessments, order blood tests and imaging when needed, and coordinate neurologist reviews and in-person specialist appointments.

Unlike Lilly's existing telehealth partnerships with Isaac Health and Synapticure, which offer specialist care, General Medicine provides a primary care starting point. Visits are available as soon as the same day and cost an average of $25 with insurance, per Lilly’s website.

Why it matters: Faster access to initial evaluations could help patients start the Alzheimer's diagnostic process while they’re still eligible for treatment. Both FDA-approved Alzheimer’s drugs Lilly’s Kisunla and Eisai and Biogen’s Leqembi are indicated for early symptomatic disease, so the timing of a diagnosis determines who can get them.

Specialist shortages remain a barrier. Patients seeking an initial cognitive care appointment without a clinician referral face an average wait of 17.9 weeks across 150 US neurology clinics, per an October JAMA Network Open study. General Medicine CEO TJ Parker told Endpoints News that some patients with cognitive concerns wait so long to see a specialist that they are no longer eligible for treatment.

Implications for pharma marketers: Lilly's Alzheimer's expansion shows how pharma companies can adapt D2C programs to guide patients through longer, more complex paths to diagnosis and treatment. While GLP-1 obesity treatments have helped fuel pharma's D2C expansion, Alzheimer's requires a different approach, including cognitive assessments, diagnostic testing, and specialist care before treatment.

That means building D2C outreach around the steps patients must take before treatment: explaining the diagnostic process and directing them to appropriate care resources. That outreach also carries regulatory risks. A Senate investigation into Lilly's and Pfizer's D2C telehealth partnerships raised concerns about prescriber independence and potential conflicts of interest, which lawmakers revisited earlier this year.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.

 

You've read 0 of 2 free articles this month.

Get more articles - create your free account today!